The MIKA platform was developed by specialists of the Department of Pre-Clinical and Clinical Research FSBI «Petrov Research Institute of Oncology»
of the Ministry of Healthcare of the Russian Federation, under the leadership of Artem Nikolayevich Poltoratskii.
FSBI «Petrov Research Institute of Oncology» conducts more than 100 clinical studies of drugs of different phases. The clinical trials of antitumor drugs are initiated by foreign and Russian pharmaceutical companies which support the development of this sphere.
Getting a new modern antitumor drug is a chance to stop the development of the disease and improve the quality of life.
Apply and our specialists will find a suitable clinical study.